Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

WESTLAKE VILLAGE, Calif. - The U.S. Food and Drug Administration has accepted Arcutis Biotherapeutics’ (NASDAQ:ARQT) supplemental New Drug Application for ZORYVE cream 0.3% to treat plaque psoriasis ...

If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 WESTLAKE VILLAGE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in child ...

Arcutis Biotherapeutics surges on strong Q3 results, Zoryve growth, and a bullish FY 2026 outlook. Click here to find out why ...

The sNDA was supported by data from a 4 week MUSE study and a long-term open-label study in children aged 2 to 5 years.

Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock rose 4.5% on Monday after the FDA accepted the company’s application to expand the use of its psoriasis treatment to younger children.

“Skin that is overexposed to cold weather can impact skin integrity and agitate existing skin conditions, such as eczema or ...

To find out if you're eligible for the Shingles vaccine, details can be found here: Dr Kas discussed the shingles rash and ...